DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Dianthus Therapeutics, Inc. /DE/

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$74.54+2.45 (+3.40%)

Close on Oct 19, 2026

Market cap: $4.18B
P/E (TTM): –
Dividend yield: 0.00%

Dianthus Therapeutics, Inc. /DE/ cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Depreciation & Amortization	–	–	–	1.93	2.02	1.98	1.84	0.88	0.38	0.01
Stock-Based Compensation	23	13	2.90	1.52	10	9.94	10	11	2.26	0.66
Change in Accounts Receivable	-0.05	0	–	–	–	–	–	–	–	–
Change in Accounts Payable	–	–	–	-0.80	-0.72	0.95	0.15	2.50	-1.13	1.01
Change in Unearned Revenue	4.57	2.39	0	0.89	–	–	–	–	–	–
Operating Cash Flow	-129	-78	-37	-29	-60	-64	-57	-42	-22	-6.53
Capital Expenditures	–	–	–	-0.31	-1.26	-0.40	-3.06	-7.67	-2.20	-0.14
Sale of Property, Plant & Equipment	–	–	–	–	–	–	–	0.01	–	–
Purchase of Investments	-435	-414	-57	-69	-45	-96	-144	-84	–	–
Sale & Maturity of Investments	–	–	–	60	90	86	149	–	–	–
Investing Cash Flow	-123	-287	20	-60	43	-11	1.53	-92	-2.20	-0.14
Stock Issued	0.32	0	0	2.90	0	65	61	93	–	–
Financing Cash Flow	280	256	134	97	90	68	62	142	71	11
Net Change in Cash	28	-109	117	7.79	73	-6.92	6.73	8.56	47	4.04
Free Cash Flow	–	–	–	-29	-61	-64	-60	-50	-24	-6.67
Income Taxes Paid	0	0	0	0	–	–	–	–	–	–
Interest Paid	0	0	0	0	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -10699.6%
Net margin: -9442.3%
Return on equity, FY2025: -38.4%

Financial strength

Current ratio: 26.10
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 321.5%

Valuation

P/E ratio: –
Price to sales: 2051.28
Price to book: 3.56
Dividend yield: 0.00%